Oculis Holding (OCS) AI Stock Analysis

• Market Cap: $992.51M
• Dividend Yield: N/A
• Average Volume (3M): 13.21K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.38
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 49
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.86
• Shares Outstanding: 54,533,672
• 10 Day Avg. Volume: 14,640
• 30 Day Avg. Volume: 13,206
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.72
• Enterprise Value/Revenue: 1.53K
• Enterprise Value/Gross Profit: -26.59
• Enterprise Value/Ebitda: -8.30
• 1Y Price Target: $36.25
• Price Target Upside: 102.06% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 31 Underperform
• Price Target: ―

Oculis Holding's stock performance is primarily hindered by severe financial challenges, with negative margins and declining equity. Technical analysis presents mixed signals, with some short-term upward movement but potential bearish momentum. The valuation is weak due to negative earnings and no dividend yield. Overall, significant improvements are needed in financial performance to enhance stock appeal.

Positive Factors

Market Potential

Privosegtor demonstrated a neuroprotection effect by reducing retinal thinning and improving visual benefits in patients with acute optic neuritis.

Regulatory Progress

Management has made a strategic decision to submit the New Drug Application for OCS-01 for the treatment of inflammation and pain following ocular surgery after the NDA submission for diabetic macular edema.

Strategic Expansion

The company has strengthened its position with three strong assets, expanding from the initial two assets.

Negative Factors

Clinical Trial Risks

Risks include possible failure of OCS-01 or OCS-02 in clinical trials or to secure regulatory approval, as well as potential dilution risk.

Regulatory Challenges

Possible failure to secure regulatory approval for OCS-01 or OCS-02 may impact the company's growth prospects.

Oculis Holding Business Overview & Revenue Model

Company Description

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

How the Company Makes Money

Oculis Holding generates revenue primarily through the development and commercialization of its proprietary ophthalmic therapies. The company's revenue model includes income from the sale of approved drug products, licensing agreements, and strategic partnerships. Oculis collaborates with other pharmaceutical companies to co-develop and market its treatments, often involving upfront payments, milestone payments, and royalties on sales. Additionally, the company may receive funding from research grants and government programs aimed at supporting innovative healthcare solutions.

Oculis Holding Financial Statement Overview

Summary

Oculis Holding faces substantial financial challenges, particularly in profitability and revenue growth, with negative margins across the board. While the company maintains a low debt-to-equity ratio, its equity has been declining. Cash flows are under pressure, with negative free cash flow and limited conversion of losses into operational cash flow. Strategic adjustments are necessary to improve financial health.

Income Statement

Oculis Holding's TTM (Trailing-Twelve-Months) income statement shows a gross profit margin of -5747.54% and a net profit margin of -18363.60%, indicating significant operational losses. The revenue growth rate is negative, showing a decrease of 47.11% from the previous year, and both EBIT and EBITDA margins are negative, further emphasizing ongoing financial struggles.

Balance Sheet

The balance sheet reveals a debt-to-equity ratio of 0.02, indicating low leverage, but stockholders' equity has decreased significantly over recent years. The equity ratio is 60.96%, showing a strong equity position relative to total assets, yet the company has faced equity erosion over time.

Cash Flow

Cash flow analysis shows a negative free cash flow growth rate of -11.43%. The operating cash flow to net income ratio is 0.55, reflecting operational inefficiencies. The free cash flow to net income ratio is 0.56, suggesting limited cash flow generation relative to net losses.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	467.00K	883.00K	912.00K	960.00K	993.00K
Gross Profit	-26.85M	-28.36M	-21.31M	-8.61M	-8.34M
EBITDA	-86.00M	-45.73M	-31.95M	-12.98M	-12.10M
Net Income	-85.78M	-88.80M	-38.70M	-18.55M	-14.87M
Balance Sheet
Total Assets	120.35M	114.35M	37.06M	58.04M	16.38M
Cash, Cash Equivalents and Short-Term Investments	98.66M	91.65M	19.79M	46.28M	4.95M
Total Debt	1.18M	605.00K	123.08M	114.27M	54.81M
Total Liabilities	46.97M	20.63M	135.05M	119.00M	60.04M
Stockholders Equity	73.38M	93.73M	-97.99M	-60.95M	-43.65M
Cash Flow
Free Cash Flow	-47.73M	-53.89M	-28.62M	-13.85M	-12.05M
Operating Cash Flow	-47.50M	-53.84M	-25.07M	-13.82M	-12.03M
Investing Cash Flow	-17.56M	-54.21M	-3.55M	-28.00K	-19.00K
Financing Cash Flow	54.03M	129.67M	1.71M	55.19M	4.86M

Oculis Holding Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 17.94
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OCS, the sentiment is Neutral. The current price of 17.94 is above the 20-day moving average (MA) of 17.93, below the 50-day MA of 18.80, and below the 200-day MA of 18.36, indicating a neutral trend. The MACD of -0.28 indicates Negative momentum. The RSI at 46.15 is Neutral, neither overbought nor oversold. The STOCH value of 37.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OCS.

Oculis Holding Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVXL	62 Neutral	$930.19M	―	-40.13%	―	―	-3.08%
EYPT	57 Neutral	$749.36M	―	-73.95%	―	12.04%	-31.81%
OCUL	53 Neutral	$1.91B	―	-63.41%	―	-0.33%	-3.59%
MLYS	53 Neutral	$874.00M	―	-56.31%	―	―	-106.10%
Sector *	51 Neutral	$7.39B	0.40	-62.86%	2.37%	15.56%	-1.99%
BCAX	48 Neutral	$619.53M	―	34.94%	―	―	―
OCS	31 Underperform	$992.51M	―	-85.39%	―	―	―